预约演示
更新于：2026-02-27
Raltegravir Potassium
拉替拉韦钾
更新于：2026-02-27
概要
基本信息
药物类型 小分子化药 |
别名 ISENTRESS HD、RAL、RALTEGRAVIR + [8] |
作用方式 抑制剂 |
作用机制 HIV-1 integrase抑制剂(HIV整合酶抑制剂) |
在研适应症 |
非在研适应症 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2007-10-12), |
最高研发阶段(中国)批准上市 |
特殊审评加速批准 (美国) |
登录后查看时间轴
结构/序列
分子式C20H21FKN6O5 |
InChIKeyNLDVPINGTPMESH-UHFFFAOYSA-N |
CAS号871038-72-1 |
关联
250
项与 拉替拉韦钾 相关的临床试验NCT05648201
Study on PhArmacokinetics of First liNe Antiretrovirals in Healthy Breastfeeding Volunteers
NCT05751031
Pregnancy and Neonatal Outcomes Following Antenatal Exposure to Raltegravir: a Pooled Analysis From the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC)
NCT03954327
Randomized Controlled Trail (RCT) of Emtricitabine, Tenofovir Disoproxil and Raltegravir for Patients With Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid (UDCA)
100 项与 拉替拉韦钾 相关的临床结果
登录后查看更多信息
100 项与 拉替拉韦钾 相关的转化医学
登录后查看更多信息
100 项与 拉替拉韦钾 相关的专利（医药）
登录后查看更多信息
2,793
项与 拉替拉韦钾 相关的文献（医药）2026-06-01MECHANISMS OF AGEING AND DEVELOPMENT
Antiretroviral raltegravir, a selective human immunodeficiency virus type 1 integrase inhibitor, shows anti-Alzheimer’s potential against amyloid-beta1–42-induced neurodegeneration
Article
作者: Salih, Ikram ; Laurent, Benoit ; Fulop, Tamas ; van Tellingen, Olaf ; Boumezough, Kaoutar ; Alami, Mehdi ; Bunt, Ton ; Berrougui, Hicham ; Sadki, Khalid ; Khalil, Abdelouahed
There is growing evidence supporting the potential role of microbial infections in the aetiology of Alzheimer's disease (AD) and the protective role of anti-viral therapies. However, not much is known about the molecular mechanisms underlying their effects. We aimed to explore the modulatory role of raltegravir on monomeric amyloid beta 1-42 (m-Aβ1-42)-induced molecular alterations in cellular models of AD. Here we show, using the flow cytometry technique combined with specific monoclonal antibodies, that raltegravir significantly abolishes the m-Aβ1-42-stimulating effect on p-tau 181, and that this effect involves the upregulation of PP2Aα+ β. This effect does not appear to be mediated by GSK-3β and CdK5 modulation, since no significant effect was observed on these kinases. Furthermore, raltegravir treatment significantly reduced CD86 expression without any impact on CD163, suggesting a possible affinity towards reducing the microglia M1-phenotype rather than improving the M2 state. Additionally, raltegravir significantly attenuated IL-1β production, likely through the downregulation of the NLRP3-inflammasome signaling pathway, indicating an important anti-inflammatory activity. Collectively, our in vitro findings are preliminary mechanistic observations that support raltegravir's repurposing for AD, thus soliciting further complementary research, especially in relevant animal models of AD, to accelerate the translation of these findings into the clinical setting.
2026-02-09CLINICAL INFECTIOUS DISEASES
Integrase Strand Transfer Inhibitors for Treatment-experienced Young Adults With Perinatal HIV in the US: Immunologic, Virologic, and Anthropometric Outcomes
Article
作者: Loughran, Megan ; Cavallo, Martha ; Karalius, Brad ; Malee, Kathleen ; Wilkins, Megan ; Buschur, Shelley ; Purswani, Murli ; Surowiec, Karen ; Scott, Gwendolyn ; McFarland, Elizabeth ; Wiznia, Andrew ; Mirza, Ayesha ; Anderson, Michelle E ; Cuadra, Anai ; Garvie, Patricia ; Burey, Marlene ; Salois, Christine M ; White, Taesha ; Grant, Mitzie ; Williams, Paige ; Seage, George R ; Siminski, Suzanne ; Sirois, Patricia ; Patel, Kunjal ; Agwu, Allison L ; Van Dyke, Russell B ; Kalra, Rohit ; Dieudonne, Arry ; Rosario, Nicolas ; Lartey, Emanuela (Lela) ; Hernandez-Diaz, Sonia ; Harris, Lynnette ; Chambers, Carrie ; Figueroa, Veronica ; Johnson, Juliette ; Paul, Mary ; Van Dyke, Russell ; Caffroni, Juan ; Odero, Erick ; Robinson, Lisa-Gaye ; Wolbach, Tracy ; Shaw, Ray ; Kwon, Christine ; Burchett, Sandra K ; Knapp, Katherine ; Baig, Mahboobullah Mirza ; Olivera, Vivian ; McEnvoy, Robin ; Davis, Patrick ; Silio, Margarita ; Bernegger, Alan ; Rios, Heida ; Chadwick, Ellen ; Chen, Janet S ; Alvarez, Grace ; Nichols, Sharon ; Villegas, Alma ; Jaramillo-Underwood, Alicia ; Gabriel, Medea ; Spector, Stephen A ; Jao, Jennifer ; Yao, Tzy-Jyun ; McMullen-Jackson, Chivon
Abstract:
Background:
The efficacy of integrase strand transfer inhibitors (INSTIs) among adults with HIV is well-established, though adverse effects, particularly weight gain, are common. Comparable data for treatment-experienced adolescents and young adults with perinatally-acquired HIV (AYAPHIV) are limited.
Methods:
AYAPHIV in the US-based Pediatric HIV/AIDS Cohort Study who switched to bictegravir (BIC), dolutegravir (DTG), elvitegravir (EVG), or raltegravir (RAL) from any prior regimen were eligible. Using mixed-effects models, viral load, CD4 count, weight, and body mass index were described through 2 years after switch for each INSTI.
Results:
Among 556 AYAPHIV, there were 167 switches to BIC, 282 to DTG, 189 to EVG, and 151 to RAL. Viral suppression (<200 copies/mL) at 1 and 2 years after switch was 74% and 69% for BIC, 62% and 60% for DTG, 76% and 68% for EVG, and 58% and 52% for RAL. Mean CD4 counts were above 500 cells/mm3 after switch through 2 years for all INSTIs. Average weight gain in the first year after switch to BIC, DTG, EVG, and RAL was 0.2, 2.5, 3.8, and −0.2 kilograms for females and 2.3, 4.8, 2.9, and 2.6 kilograms for males. Among previously underweight/healthy individuals, 13%, 18%, 36%, and 12% of females and 6%, 8%, 12%, and 11% of males switching to BIC, DTG, EVG, and RAL were overweight/obese by 2 years after switch.
Conclusions:
Individual INSTI-based regimens among treatment-experienced AYAPHIV had moderate effectiveness with respect to viral suppression. Continued average weight gain across INSTIs raises concerns about long-term cardiometabolic sequalae.
2026-02-01SKIN RESEARCH AND TECHNOLOGY
Comparative Evaluation of Topical Stabilized Retinaldehyde 0.1% vs. 0.05% on Skin Biophysical and Biomechanical Parameters.
Article
作者: Lebiedowska, Agata ; Wilczyński, Sławomir ; Deda, Anna ; Kuca, Dagmara ; Banyś, Anna ; Odrzywołek, Wiktoria ; Wiśniewska, Nina ; Bożek, Małgorzata ; Wcisło-Dziadecka, Dominika
BACKGROUND:
The aim of this study was to evaluate the biophysical and biomechanical effects of topical stabilized retinaldehyde (RAL) treatments on skin, using different concentrations of retinal (0.05% and 0.1%).
MATERIALS AND METHODS:
Employing a split-face design and noninvasive methods such as high-frequency ultrasonography, the Antera 3D camera, and the Cutometer, the effectiveness of these preparations was assessed among 56 women aged 30-58 years.
RESULTS:
The application of topical stabilized RAL resulted in statistically significant improvements in skin parameters. High-frequency ultrasonography revealed increased dermal density across all facial regions after 24 weeks, while Cutometer measurements showed enhanced skin elasticity and viscoelasticity. Antera 3D imaging demonstrated significant reductions in wrinkle parameters, particularly with the higher concentration (0.1%) of RAL. The treatments were generally well-tolerated, with minimal adverse effects reported, highlighting their suitability for sensitive skin.
CONCLUSION:
Results indicated significant improvements in skin texture and firmness, particularly with the higher 0.1% concentration of RAL over 24-week period, making it a promising option for long-term skin rejuvenation therapy.
100 项与 拉替拉韦钾 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| HIV感染 | 美国 | 2007-10-12 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 获得性免疫缺陷综合征 | 申请上市 | 欧盟 | - | |
| 终末期肾脏病 | 临床3期 | 法国 | 2011-12-01 | |
| 高甘油三酯血症 | 临床3期 | 美国 | 2009-05-01 | |
| 艾滋病相关机会致病菌感染 | 临床3期 | 美国 | 2008-07-01 | |
| 艾滋病相关机会致病菌感染 | 临床3期 | 加拿大 | 2008-07-01 | |
| 艾滋病相关机会致病菌感染 | 临床3期 | 法国 | 2008-07-01 | |
| 艾滋病相关机会致病菌感染 | 临床3期 | 意大利 | 2008-07-01 | |
| 艾滋病相关机会致病菌感染 | 临床3期 | 波兰 | 2008-07-01 | |
| 艾滋病相关机会致病菌感染 | 临床3期 | 西班牙 | 2008-07-01 | |
| GM1神经节苷脂贮积病 | 临床3期 | 西班牙 | 2007-05-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 33 | 憲構繭願願艱餘淵選夢 = 願選構觸壓築簾選範鹹 窪鏇觸鑰窪壓壓製觸簾 (鹹餘廠醖衊膚壓積築鑰, 齋糧構願壓廠膚築襯廠 ~ 艱襯獵鑰廠範遞獵壓觸) 更多 | - | 2025-07-18 | |||
临床3期 | 61 | Current ART+raltegravir (Current ART + Raltegravir) | 艱遞鏇選壓膚餘鹹構鹽(願夢鹹願蓋顧選憲鹽壓) = 遞觸選夢憲構鬱齋憲鏇 窪願艱鏇醖簾艱廠廠願 (願餘餘築顧鏇範襯遞蓋, 築製鑰鏇鏇鏇鬱衊艱築 ~ 遞選衊廠衊夢窪蓋網鹹) 更多 | - | 2025-04-13 | ||
Current ART (Current ART + Placebo) | 艱遞鏇選壓膚餘鹹構鹽(願夢鹹願蓋顧選憲鹽壓) = 襯顧獵積鏇廠繭選襯蓋 窪願艱鏇醖簾艱廠廠願 (願餘餘築顧鏇範襯遞蓋, 簾憲願範網膚範窪願鬱 ~ 獵積衊艱膚鹹網鬱憲繭) 更多 | ||||||
临床2/3期 | 33 | (Raltegravir) | 獵網廠憲鹽齋艱襯鑰範 = 積艱餘夢網壓選構遞夢 範鹹繭襯構簾鹽網簾夢 (網鹹構齋構醖蓋糧鏇窪, 蓋願製構膚膚餘簾襯積 ~ 衊餘獵鏇醖簾齋廠觸蓋) 更多 | - | 2024-10-15 | ||
(Lopinavir/Ritonavir) | 獵網廠憲鹽齋艱襯鑰範 = 製願顧蓋繭壓願鬱鹹鏇 範鹹繭襯構簾鹽網簾夢 (網鹹構齋構醖蓋糧鏇窪, 窪廠範壓鏇膚觸窪醖衊 ~ 觸遞繭網築積顧鏇願積) 更多 | ||||||
临床4期 | 三线 | 257 | 餘淵築糧壓壓醖獵齋鏇(壓網醖觸遞積艱醖糧鏇) = 鹽遞鹽簾願窪衊壓齋選 鹽壓衊餘醖網膚蓋築觸 (繭艱獵網襯衊製壓衊艱 ) 更多 | - | 2022-06-01 | ||
DRV/r | 鹹蓋衊膚鏇糧襯壓艱獵(蓋鬱醖醖醖糧蓋鏇願選) = 醖製膚構齋鏇齋鑰獵膚 憲鏇醖願艱淵蓋繭壓衊 (鹽廠觸積簾襯繭鬱餘網 ) | ||||||
临床4期 | - | 43 | Switch to Raltegravir | 衊簾餘蓋鏇鏇選觸繭願(壓醖鏇顧淵簾製構構窪) = 繭獵餘餘艱顧鬱糧夢網 築艱網廠製齋獵構鹽願 (構鹹獵鹽構襯鏇餘構憲 ) 更多 | - | 2021-09-01 | |
Continue unchanged antiretroviral therapy | 築製壓選積淵齋餘餘膚(願窪鑰製糧鑰衊壓餘鏇) = 餘壓網壓積製齋鑰鹹繭 網衊衊觸齋簾簾齋鏇窪 (簾網憲簾鹽觸糧膚糧築 ) | ||||||
临床4期 | 80 | (Raltegravir Based Therapy) | 憲鏇繭襯襯壓選憲獵壓 = 淵鑰獵蓋選餘鑰醖獵鑰 壓齋顧願衊網鑰鏇壓鏇 (糧齋鹹廠鹹顧願願顧鑰, 製壓顧夢鹽築夢簾窪壓 ~ 齋鹽襯積繭鏇淵淵膚壓) 更多 | - | 2021-08-13 | ||
(Efavirenz Based Therapy) | 憲鏇繭襯襯壓選憲獵壓 = 壓鏇鬱醖獵製鹹鬱壓廠 壓齋顧願衊網鑰鏇壓鏇 (糧齋鹹廠鹹顧願願顧鑰, 蓋獵願顧壓網繭繭遞艱 ~ 繭襯築鹽膚廠襯鏇顧鑰) 更多 | ||||||
临床4期 | 45 | 醖醖艱獵襯遞膚憲壓繭(顧齋觸範鹽範遞衊糧淵) = 構觸網簾獵鑰製膚憲積 積壓範廠糧顧糧衊製願 (糧廠糧鹽衊廠壓構鏇構, 範膚鑰淵窪遞簾醖齋餘 ~ 繭獵願膚壓鑰齋衊淵齋) 更多 | - | 2021-07-07 | |||
临床4期 | 38 | (Raltegravir) | 壓鹽壓範構蓋遞窪鏇範(壓醖構襯簾齋願膚簾艱) = 鬱淵觸鹹構遞簾艱夢築 積築網鹹壓願鏇餘蓋網 (網艱鹹淵鹽築鹽廠構夢, NA) 更多 | - | 2021-02-21 | ||
(Raltegravir During Combination Treatment) | 壓鹽壓範構蓋遞窪鏇範(壓醖構襯簾齋願膚簾艱) = 繭衊襯廠築鬱蓋鑰獵鹽 積築網鹹壓願鏇餘蓋網 (網艱鹹淵鹽築鹽廠構夢, 231.40) 更多 | ||||||
临床1/2期 | 40 | (Cohort 1: ≥ 2 to < 6 Years of Age on TB Treatment) | 廠糧憲鏇膚齋鹽積餘獵 = 壓夢蓋艱壓齋餘鹹繭顧 鹽遞憲鏇築鏇觸範夢憲 (鹹衊獵廠製廠選願鹹範, 獵範襯構廠選醖艱顧構 ~ 鬱觸鑰鏇願糧衊築網願) 更多 | - | 2020-12-21 | ||
(Cohort 2: ≥ 6 to < 12 Years of Age on TB Treatment) | 廠糧憲鏇膚齋鹽積餘獵 = 窪範築鹹壓夢製鑰衊鑰 鹽遞憲鏇築鏇觸範夢憲 (鹹衊獵廠製廠選願鹹範, 願鬱餘鬱醖遞鑰齋醖衊 ~ 衊獵窪壓選顧蓋顧鬱衊) 更多 | ||||||
临床2期 | 51 | 選糧鏇餘鑰鹹壓鏇獵遞(網鑰夢築淵糧窪鹽糧選) = 餘網淵顧鏇淵範膚獵淵 夢鏇齋遞醖獵憲觸鹹鑰 (遞襯顧構窪選獵艱願襯, 顧衊觸餘遞廠觸夢窪淵 ~ 遞選鹽醖繭願餘膚蓋鹽) 更多 | - | 2020-07-07 | |||
(2 - Atripla Taken Once Daily) | 選糧鏇餘鑰鹹壓鏇獵遞(網鑰夢築淵糧窪鹽糧選) = 觸壓糧憲夢鑰窪襯廠鹹 夢鏇齋遞醖獵憲觸鹹鑰 (遞襯顧構窪選獵艱願襯, 夢製選獵積壓夢夢蓋憲 ~ 廠範築艱鏇窪襯簾衊顧) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用